Aylin Akifova

Aylin Akifova

Auto-generated profile, based on publicly available information

Aylin Akifova

Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2024 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
AAAylin Akifova
Aylin Akifova
KBKlemens Budde
Klemens Budde
KAKerstin Amann
Kerstin Amann
MBMaike Buettner-Herold
Maike Buettner-Herold
MCMira Choi
Mira Choi
BOBilgin Osmanodja
Bilgin Osmanodja
Background: Donor-derived cell-free DNA (dd-cfDNA) shows good diagnostic performance for the detection of antibody-mediated rejection (AMR) in kidney transplant recipients (KTR). However, the clinical benefits of dd-cfDNA monitoring need to be established. Early diagnosis of AMR at potentially reversible stages may be increasingly important due to emerging treatment options for AMR. We hypothesized that monitoring dd-cfDNA in KTR with de novo donor-specific anti-HLA antibodies (dnDSA) and performing kidney biopsy in case of increased dd-cfDNA may reduce time to AMR diagnosis in comparison with clinical indication biopsy. Methods: In this diagnostic, single-center, open-label, randomized clinical trial, we assigned 40 KTR with prevalent dnDSA and estimated glomerular filtration rate ≥20 mL/min/1.73 m2, but without previous biopsy-proven AMR, to either dd-cfDNA-guided biopsy (intervention group) or clinician-guided biopsy (control group) over a 12-month period. In both groups, dd-cfDNA was assessed at inclusion and 1, 3, 6, 9 and 12 months. In the intervention group, dd-cfDNA >50 copies/mL indicated a biopsy. Biopsies for clinical indication could be performed at any point during the study period in both groups. A protocol biopsy was scheduled after 12 months for patients without dd-cfDNA-guided biopsy or clinical indication biopsy until study completion. The primary endpoint was time from study inclusion to diagnosis of active or chronic active AMR. Results: Thirty-nine of 40 patients had functioning grafts at study completion. From these, 26 patients underwent biopsy, 13 in each group. AMR was diagnosed earlier in the intervention group than in the control group [median 2.8 months, interquartile range (IQR) 1.7–5.3 vs median 14.5 months, IQR 13.3–16.7, P = .003]. Longitudinal dd-cfDNA monitoring had 77% positive predictive value and 85% negative predictive value for AMR. Conclusions: Dd-cfDNA-guided biopsy in KTR with prevalent dnDSA can reduce the time to AMR diagnosis and hereby expedite therapy initiation. Trial registration: ClinicalTrials.gov, NCT04897438.

12 August 2024 in Transplant International
Verified
Journal Article
Open access
PDF file
AAAylin Akifova
Aylin Akifova
KBKlemens Budde
Klemens Budde
MOMichael Oellerich
Michael Oellerich
JBJulia Beck
Julia Beck
KBKirsten Bornemann-Kolatzki
Kirsten Bornemann-Kolatzki
BOBilgin Osmanodja
Bilgin Osmanodja
Antibody-mediated rejection (AMR) is a major cause of graft failure limiting long-term graft survival after kidney transplantation. Current diagnostic strategy to detect AMR is suboptimal and requires further improvement. Previously suggested treatment regimens for AMR could not demonstrate efficacy, however novel therapeutic agents are currently under investigation. Donor-derived cell-free DNA (dd-cfDNA) is a novel non-invasive biomarker for allograft injury, that has been mainly studied in the context of rejection. Its short-half-life in circulation and injury-dependent release are its key advantages that contribute to its superior diagnostic accuracy, compared to traditional biomarkers. Moreover, previous studies showed that dd-cfDNA-release is well-linked to histological and molecular features of AMR, and thus able to reflect real-time injury. Further observations suggest that dd-cfDNA can be used as a suitable screening tool for early detection of AMR in patients with donor-specific-anti-HLA-antibodies (DSA), as well as for monitoring AMR activity after anti-rejection treatment. The weight of evidence suggests that the integration of dd-cfDNA in the graft surveillance of patients with AMR, or those suspicious of AMR (e.g., due to the presence of donor-specific anti-HLA-antibodies) has an added value and might have a positive impact on outcomes in this specific cohort.

10 April 2025 in Transplantation Direct
Verified
Journal Article
Open access
AAAylin Akifova
Aylin Akifova
KBKlemens Budde
Klemens Budde
MCMira Choi
Mira Choi
KAKerstin Amann
Kerstin Amann
MBMaike Julia Büttner-Herold
Maike Julia Büttner-Herold
BOBilgin Osmanodja
Bilgin Osmanodja
Background. Donor-derived cell-free DNA (dd-cfDNA) is an emerging biomarker of kidney allograft injury, mainly investigated in the context of rejection. However, the dd-cfDNA dynamics in other graft pathologies merit further investigation. Methods. In this single-center observational study, we prospectively collected dd-cfDNA at indication biopsies. To evaluate the association between dd-cfDNA and different histological patterns, we correlated absolute and relative dd-cfDNA (thresholds of 50 copies/mL and 0.5%, respectively) with the Banff 2022 lesion scores and the assigned diagnoses. Results. We examined 151 dd-cfDNA paired biopsies in 131 kidney transplant recipients and found significantly higher absolute dd-cfDNA levels in antibody-mediated rejection (n, median, IQR: 45, 63 copies/mL, 42–89), microvascular inflammation (MVI) without donor-specific antibodies or C4d-deposition (6, 102 copies/mL, 61–134), mixed rejection (8, 140 copies/mL, 77–171), and BK virus–associated nephropathy (6, 213 copies/mL, 83–298) compared with glomerulonephritis (20, 12 copies/mL, 8–18), calcineurin toxicity (19, 10 copies/mL, 7–16), interstitial fibrosis/tubular atrophy (12, 10 copies/mL, 9–16) and normal histology (6, 9 copies/mL, 7–16). In the multivariable analysis, absolute and relative dd-cfDNA correlated with the peritubular capillaritis (ptc), glomerulitis (g), and tubulitis (t) scores. In the receiver operating characteristic analysis, absolute dd-cfDNA showed best discrimination for MVI of any cause (area under the curve [AUC] 0.88, sensitivity 0.71, specificity 0.86, positive predictive value [PPV] 0.76, negative predictive value [NPV] 0.82), followed by antibody-mediated rejection including mixed rejection (AUC 0.85, sensitivity 0.72, specificity 0.83, PPV 0.69, NPV 0.84), and overall rejection (AUC 0.83, sensitivity 0.66, specificity 0.85, PPV 0.76, NPV 0.77). T cell–mediated rejection was only detectable by dd-cfDNA when associated with vascular lesions. Conclusions. Altogether, we conclude that dd-cfDNA-release is not limited to rejection-related injury phenotypes and is mainly driven by MVI in kidney allografts. Export

22 March 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BOBilgin Osmanodja
Bilgin Osmanodja
AAAylin Akifova
Aylin Akifova
MOMichael Oellerich
Michael Oellerich
JBJulia Beck
Julia Beck
KBKirsten Bornemann-Kolatzki
Kirsten Bornemann-Kolatzki
KBKlemens Budde
Klemens Budde
Donor-derived cell-free DNA (dd-cfDNA) is used as a biomarker for detection of antibody-mediated rejection (ABMR) and other forms of graft injury. Another potential indication is guidance of immunosuppressive therapy when no therapeutic drug monitoring is available. In such situations, detection of patients with overt or subclinical graft injury is important to personalize immunosuppression. We prospectively measured dd-cfDNA in 22 kidney transplant recipients (KTR) over a period of 6 months after conversion to belatacept for clinical indication and assessed routine clinical parameters. Patient and graft survival was 100% after 6 months, and eGFR remained stable (28.7 vs. 31.1 mL/min/1.73 m2, p = 0.60). Out of 22 patients, 2 (9%) developed biopsy-proven rejection—one episode of low-grade TCMR IA and one episode of caABMR. While both episodes were detected by increase in creatinine, the caABMR episode led to increase in absolute dd-cfDNA (168 copies/mL) above the cut-off of 50 copies/mL, while the TCMR episode did show slightly increased relative dd-cfDNA (0.85%) despite normal absolute dd-cfDNA (22 copies/mL). Dd-cfDNA did not differ before and after conversion in a subgroup of 12 KTR with previous calcineurin inhibitor therapy and no rejection (12.5 vs. 25.3 copies/mL, p = 0.34). In this subgroup, 3/12 (25%) patients showed increase of absolute dd-cfDNA above the prespecified cut-off (50 copies/mL) despite improving eGFR. Increase in dd-cfDNA after conversion to belatacept is common and could point towards subclinical allograft injury. To detect subclinical TCMR changes without vascular lesions, additional biomarkers or urinary dd-cfDNA should complement plasma dd-cfDNA. Resolving CNI toxicity is unlikely to be detected by decreased dd-cfDNA levels. In summary, the sole determination of dd-cfDNA has limited utility in the guidance of patients after late conversion to belatacept. Further studies should focus on patients undergoing early conversion and include protocol biopsies at least for patients with increased dd-cfDNA.

20 July 2023 in Kidney International Reports
Verified
Journal Article
Open access
AAAylin Akifova
Aylin Akifova
KBKlemens Budde
Klemens Budde
MCMira Choi
Mira Choi
MOMichael Oellerich
Michael Oellerich
JBJulia Beck
Julia Beck
BOBilgin Osmanodja
Bilgin Osmanodja

12 December 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
YLYannis Lombardi
Yannis Lombardi
MRMarc Raynaud
Marc Raynaud
MSMartina Schatzl
Martina Schatzl
KMKatharina Mayer
Katharina Mayer
MDMatthias Diebold
Matthias Diebold
GBGeorg A. Böhmig
Georg A. Böhmig